FLEXION PERMANENT PACING LEAD
Report
- Report Number
- 1035166-2025-00054
- Event Type
- Injury
- Date Received
- November 13, 2025
- Date of Event
- October 23, 2025
- Report Date
- November 13, 2025
- Manufacturer
- INTEGER
- Product Code
- DTB
- PMA / PMN Number
- K964107
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- MN, US
- Reporter Occupation
- 003
Narratives
THE LEAD WAS USED IN TREATMENT FOR APPROXIMATELY 24 YEARS, 2 MONTHS BEFORE BEING EXPLANTED ON (B)(6) 2025, FOR INFECTION. THERE WERE NO ALLEGATIONS REPORTED FOR THIS LEAD. INFECTION IS A KNOWN INHERENT RISK FOR THE IMPLANTABLE DEVICE(S). THIS LEAD IS SUPPLIED STERILE. THE FOLLOWING CONTROLS ARE IN PLACE TO ENSURE THE INTEGRITY OF THE STERILE LEAD AND IT'S PACKAGING. THE FINAL LABELING AND PACKAGING INSPECTION PROCEDURE INDICATES ALL LABELING AND PACKAGING WILL BE INSPECTED 100%. SHAKE THE OUTER TRAY BY HOLDING TAB OF OUTER TRAY TO ENSURE INNER TRAY IS LOOSE INSIDE THE OUTER TRAY. CHECK FOR FOREIGN MATERIAL AND TYVEK SEAL INTEGRITY. VERIFY THAT COLOR OF STERI-DOT CHANGED FROM BROWN TO GREEN. SEALED AREAS (TYVEK LID TO LIP OF TRAY) ARE CONTINUOUS AROUND ENTIRE PERIMETER OF TRAY. NO VOIDS, BREAKS, AND OR BUBBLES ALONG THE SEAL. THE ENTIRE SEAL SHOULD BE AT LEAST QUARTER INCH WIDE AND HAVE A FULL RIDGE. THE TYVEK PULL TAB MUST BE PROPERLY FOLDED INTO POSITION. EXAMINE THE SEAL AND BORDER FOR UNIFORMITY OF THE SEAL. CHECK FOR HOLES OR ANY OTHER DAMAGES THAT COULD VIOLATE STERILITY. THE INSTRUCTIONS FOR USE PERMANENT LEADS GENERIC BOOKLET (IFU) INFORMS THE USER THAT OSCOR'S MEDICAL DEVICES MEET ALL APPLICABLE FEDERAL REGULATIONS AND PROPOSED REGULATIONS GOVERNING STERILIZATION PRIOR TO BEING RELEASED FROM OUR FACILITY. ALL OF OSCOR'S STERILIZED PRODUCTS HAVE CONSISTENTLY PASSED BIOCOMPATIBILITY TESTS PRIOR TO RELEASE AND SHIPMENT. BASED UPON OUR TESTING OF PRODUCTS STERILIZED IN THIS MANNER, OSCOR INC. IS CONFIDENT ITS PRODUCTS ARE SAFE FOR THEIR INTENDED USE. THIS PRODUCT IS STERILIZED PRIOR TO SHIPMENT. THE STERILITY IS COMPROMISED WHEN THE PACKAGE IS OPENED OR DAMAGED. OSCOR INC. DOES NOT ASSUME ANY LIABILITY OR RESPONSIBILITY FOR STERILIZATION BY A THIRD PARTY. IN ADDITION, THE IFU LISTS INFECTION AS AN ADVERSE EFFECT: INFECTION, LEAD MAY REQUIRE SURGICAL REMOVAL. AS WITH THE INTRODUCTION OF ANY FOREIGN OBJECT INTO THE BODY, VARIOUS FORMS OF INFECTION CAN ALSO RESULT FROM THE USE OF ENDOCARDIAL OR EPICARDIAL LEADS. INFECTION IS LISTED IN THE INSTRUCTIONS FOR USE (IFU) AS AN ADVERSE EVENT THAT MAY REQUIRE SURGICAL REMOVAL OF THE LEAD. NO FURTHER FOLLOW-UP IS REQUIRED. BASED ON THE INVESTIGATION, A CAPA IS NOT REQUIRED. THIS LEAD IS NO LONGER MANUFACTURED BY OSCOR. THE EVENT WILL BE RE-EVALUATED IF ADDITIONAL INFORMATION BECOMES AVAILABLE. OSCOR WILL CONTINUE TO MONITOR THIS EVENT TYPE. INTEGER IS SUBMITTING THE ABOVE REPORT TO COMPLY WITH 21 CFR PART 803, THE MEDICAL DEVICE REPORTING REGULATION. THE REPORT IS BASED UPON INFORMATION OBTAINED BY INTEGER WHICH THE COMPANY MAY NOT HAVE BEEN ABLE TO INVESTIGATE OR VERIFY PRIOR TO THE DATE THE REPORT WAS REQUIRED BY FDA. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION THAT THE DEVICE, INTEGER, OR ITS EMPLOYEES, CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THIS REPORT. NOR DOES THIS REPORT REFLECT A CONCLUSION BY FDA, INTEGER, OR ITS EMPLOYEES, THAT THE REPORT CONSTITUTES AN ADMISSION THAT THE DEVICE, INTEGER, OR ITS EMPLOYEES CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THIS REPORT.
DEVICE G447/(B)(6), 4017/(B)(6), 0673/(B)(6) AND 4672/(B)(6) WAS EXPLANTED ON (B)(6) 2025 DUE TO INFECTION (PER REQUIRED). PRODUCT NOT RETURNING. PATIENT HAD AN INFECTION, SYSTEM WAS REMOVED. NO ADDITIONAL INFORMATION ABOUT PATIENT IMPACT AFTER THE EXPLANT. AS REPORTED DEVICE CODES: 2099: NO KNOWN DEVICE PROBLEM. AS REPORTED PATIENT CODES: 9151: INFECTION.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1923363 | FLEXION PERMANENT PACING LEAD | PERMANENT PACEMAKER ELECTRODE | DTB | INTEGER | 4017 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 71 YR | Male | Other |